Adaptive Biotechnologies and Genentech Launch Personalized Cancer-Care Program Worth $2 Billion+

Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers. The companies will combine Genentech’s noted immunotherapy research and medications with Adaptive’s proprietary T-cell receptor (TCR) discovery and immune profiling platform TruTCR to accelerate a transformational new treatment paradigm of tailoring cellular therapy for each patient’s individual cancer, the company announced this morning. Adaptive Biotechnologies Chief Executive Officer Chad Robins said he was thrilled that Genentech selected his company for a neoantigen directed T-cell therapies partnership.
“Genentech brings an industry-leading team of scientists and drug development experts who could potentially enable our patented TCR discovery and immune profiling platform to help as many patients as possible,” Robins said in a statement.